University of Hertfordshire

SASP: targeted delivery to Gram-negative pathogens

Research output: Contribution to conferencePoster

Standard

SASP: targeted delivery to Gram-negative pathogens. / Wang, H.; Hatzixanthis, K.; Barnard, A.; Shah, R.; Saveri, E.; Pitts, K.; Piwowarczyk, D.; Patil, G.; Baines, Simon D.; Wilkinson, A.; Fairhead, H.

2011. Poster session presented at 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, United States.

Research output: Contribution to conferencePoster

Harvard

Wang, H, Hatzixanthis, K, Barnard, A, Shah, R, Saveri, E, Pitts, K, Piwowarczyk, D, Patil, G, Baines, SD, Wilkinson, A & Fairhead, H 2011, 'SASP: targeted delivery to Gram-negative pathogens' 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, United States, 17/09/11 - 20/09/11, .

APA

Wang, H., Hatzixanthis, K., Barnard, A., Shah, R., Saveri, E., Pitts, K., ... Fairhead, H. (2011). SASP: targeted delivery to Gram-negative pathogens. Poster session presented at 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, United States.

Vancouver

Wang H, Hatzixanthis K, Barnard A, Shah R, Saveri E, Pitts K et al. SASP: targeted delivery to Gram-negative pathogens. 2011. Poster session presented at 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, United States.

Author

Wang, H. ; Hatzixanthis, K. ; Barnard, A. ; Shah, R. ; Saveri, E. ; Pitts, K. ; Piwowarczyk, D. ; Patil, G. ; Baines, Simon D. ; Wilkinson, A. ; Fairhead, H. / SASP: targeted delivery to Gram-negative pathogens. Poster session presented at 51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, United States.

Bibtex

@conference{eaa099674a1f41438d9d642e2ebd8bae,
title = "SASP: targeted delivery to Gram-negative pathogens",
abstract = "Background: Gram-negative bacteria are responsible for significant morbidity and mortality worldwide. Multi-drug resistance emergence has rendered many therapies ineffective. New therapies are urgently required to widen treatment options. SASPject technology delivers small acid-soluble spore protein (SASP) genes to target bacteria using modified bacteriophage vectors, resulting in rapid killing. SASP is a unique antibacterial protein that non-specifically binds bacterial DNA and halts DNA replication and gene expression. In this study we present the first data for a Gram-negative targeted SASPject vector (PT3.1) which shows in vitro activity against Escherichia coli (EC) and Pseudomonas aeruginosa (PA). Methods: We evaluated efficacy of SASPject PT3.1 vs. EC (N=5) & PA (N=5) using a microtitre tray fixed duration (3 h) kill method. Log-phase cultures (1x105 cfu/mL) were prepared in supplemented (MgSO4 & CaCl2, 5 mM; glucose, 0.1{\%} w/v) LB broth (LBC) & exposed to 2x108 plaque forming units (pfu)/mL of PT3.1. PT3.1 antimicrobial activity was determined using agar-based culture following incubation (37oC). Additionally, rate of PT3.1 kill was determined using a kill-curve technique; a selection of EC & PA strains from the fixed duration kill study were evaluated & bacterial viable counts determined over 3 h on LBC agar. Results: SASPject PT3.1 elicited good antimicrobial activity vs. EC & PA evaluated in this study; the median reduction in viable counts for PT3.1-treated cultures in the fixed 3 h kill was 99.1{\%}. Kill curve data suggested rapid EC & PA killing; viable counts (log10 cfu/mL range) of PT3.1-treated cultures were 2.36->4.01, 3.04-4.06, and 3.40-4.16 lower than corresponding controls after 1, 2, and 3 h respectively. Conclusions: 1. SASPject PT3.1 demonstrated good antimicrobial activity vs. EC & PA evaluated in this study in a fixed 3 h exposure period 2. PT3.1 was bactericidal (≥3 log10 cfu/mL decline) vs. 3 of 4 isolates (1EC & 2PA) evaluated in time-kill curves after 1 h and against all isolates after 2 h 3. Further evaluations of Gram-negative SASPject phage are warranted",
author = "H. Wang and K. Hatzixanthis and A. Barnard and R. Shah and E. Saveri and K. Pitts and D. Piwowarczyk and G. Patil and Baines, {Simon D.} and A. Wilkinson and H. Fairhead",
year = "2011",
month = "9",
language = "English",
note = "51st Interscience Conf on Antimicrobial Agents and Chemotherapy (ICAAC) ; Conference date: 17-09-2011 Through 20-09-2011",

}

RIS

TY - CONF

T1 - SASP: targeted delivery to Gram-negative pathogens

AU - Wang, H.

AU - Hatzixanthis, K.

AU - Barnard, A.

AU - Shah, R.

AU - Saveri, E.

AU - Pitts, K.

AU - Piwowarczyk, D.

AU - Patil, G.

AU - Baines, Simon D.

AU - Wilkinson, A.

AU - Fairhead, H.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Gram-negative bacteria are responsible for significant morbidity and mortality worldwide. Multi-drug resistance emergence has rendered many therapies ineffective. New therapies are urgently required to widen treatment options. SASPject technology delivers small acid-soluble spore protein (SASP) genes to target bacteria using modified bacteriophage vectors, resulting in rapid killing. SASP is a unique antibacterial protein that non-specifically binds bacterial DNA and halts DNA replication and gene expression. In this study we present the first data for a Gram-negative targeted SASPject vector (PT3.1) which shows in vitro activity against Escherichia coli (EC) and Pseudomonas aeruginosa (PA). Methods: We evaluated efficacy of SASPject PT3.1 vs. EC (N=5) & PA (N=5) using a microtitre tray fixed duration (3 h) kill method. Log-phase cultures (1x105 cfu/mL) were prepared in supplemented (MgSO4 & CaCl2, 5 mM; glucose, 0.1% w/v) LB broth (LBC) & exposed to 2x108 plaque forming units (pfu)/mL of PT3.1. PT3.1 antimicrobial activity was determined using agar-based culture following incubation (37oC). Additionally, rate of PT3.1 kill was determined using a kill-curve technique; a selection of EC & PA strains from the fixed duration kill study were evaluated & bacterial viable counts determined over 3 h on LBC agar. Results: SASPject PT3.1 elicited good antimicrobial activity vs. EC & PA evaluated in this study; the median reduction in viable counts for PT3.1-treated cultures in the fixed 3 h kill was 99.1%. Kill curve data suggested rapid EC & PA killing; viable counts (log10 cfu/mL range) of PT3.1-treated cultures were 2.36->4.01, 3.04-4.06, and 3.40-4.16 lower than corresponding controls after 1, 2, and 3 h respectively. Conclusions: 1. SASPject PT3.1 demonstrated good antimicrobial activity vs. EC & PA evaluated in this study in a fixed 3 h exposure period 2. PT3.1 was bactericidal (≥3 log10 cfu/mL decline) vs. 3 of 4 isolates (1EC & 2PA) evaluated in time-kill curves after 1 h and against all isolates after 2 h 3. Further evaluations of Gram-negative SASPject phage are warranted

AB - Background: Gram-negative bacteria are responsible for significant morbidity and mortality worldwide. Multi-drug resistance emergence has rendered many therapies ineffective. New therapies are urgently required to widen treatment options. SASPject technology delivers small acid-soluble spore protein (SASP) genes to target bacteria using modified bacteriophage vectors, resulting in rapid killing. SASP is a unique antibacterial protein that non-specifically binds bacterial DNA and halts DNA replication and gene expression. In this study we present the first data for a Gram-negative targeted SASPject vector (PT3.1) which shows in vitro activity against Escherichia coli (EC) and Pseudomonas aeruginosa (PA). Methods: We evaluated efficacy of SASPject PT3.1 vs. EC (N=5) & PA (N=5) using a microtitre tray fixed duration (3 h) kill method. Log-phase cultures (1x105 cfu/mL) were prepared in supplemented (MgSO4 & CaCl2, 5 mM; glucose, 0.1% w/v) LB broth (LBC) & exposed to 2x108 plaque forming units (pfu)/mL of PT3.1. PT3.1 antimicrobial activity was determined using agar-based culture following incubation (37oC). Additionally, rate of PT3.1 kill was determined using a kill-curve technique; a selection of EC & PA strains from the fixed duration kill study were evaluated & bacterial viable counts determined over 3 h on LBC agar. Results: SASPject PT3.1 elicited good antimicrobial activity vs. EC & PA evaluated in this study; the median reduction in viable counts for PT3.1-treated cultures in the fixed 3 h kill was 99.1%. Kill curve data suggested rapid EC & PA killing; viable counts (log10 cfu/mL range) of PT3.1-treated cultures were 2.36->4.01, 3.04-4.06, and 3.40-4.16 lower than corresponding controls after 1, 2, and 3 h respectively. Conclusions: 1. SASPject PT3.1 demonstrated good antimicrobial activity vs. EC & PA evaluated in this study in a fixed 3 h exposure period 2. PT3.1 was bactericidal (≥3 log10 cfu/mL decline) vs. 3 of 4 isolates (1EC & 2PA) evaluated in time-kill curves after 1 h and against all isolates after 2 h 3. Further evaluations of Gram-negative SASPject phage are warranted

M3 - Poster

ER -